Go Pro
→ Is This the New Normal for Gold? (From Wall Street Logic) (Ad)tc pixel Free KYMR Stock Alerts

Kymera Therapeutics (KYMR) Competitors

Kymera Therapeutics logo
$118.48 +2.15 (+1.85%)
Closing price 09/17/2026 04:00 PM Eastern
Extended Trading
$118.58 +0.10 (+0.08%)
As of 09:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KYMR vs. ALNY, BIIB, ROIV, INSM, and INCY

Should you buy Kymera Therapeutics stock or one of its competitors? Kymera Therapeutics's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Kymera Therapeutics (NASDAQ:KYMR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Kymera Therapeutics' net margin of -285.33%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -21.22% -19.21%
Alnylam Pharmaceuticals 15.26%84.93%14.30%

Kymera Therapeutics currently has a consensus target price of $131.63, indicating a potential upside of 11.09%. Alnylam Pharmaceuticals has a consensus target price of $367.20, indicating a potential upside of 49.57%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.88
Alnylam Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.87

Kymera Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for Alnylam Pharmaceuticals and 7 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.73 beat Alnylam Pharmaceuticals' score of 0.70 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alnylam Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Alnylam Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$105M93.83-$311.35M-$3.24N/A
Alnylam Pharmaceuticals$3.71B8.85$313.75M$5.3845.63

Summary

Alnylam Pharmaceuticals beats Kymera Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Biogen?

Kymera Therapeutics (NASDAQ:KYMR) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Biogen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$105M93.83-$311.35M-$3.24N/A
Biogen$9.89B3.27$1.29B$5.6538.77

Kymera Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Biogen has a net margin of 8.32% compared to Kymera Therapeutics' net margin of -285.33%. Biogen's return on equity of 11.18% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -21.22% -19.21%
Biogen 8.32%11.18%6.88%

Kymera Therapeutics currently has a consensus target price of $131.63, indicating a potential upside of 11.09%. Biogen has a consensus target price of $230.14, indicating a potential upside of 5.06%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.88
Biogen
1 Sell rating(s)
13 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
2.58

In the previous week, Biogen had 15 more articles in the media than Kymera Therapeutics. MarketBeat recorded 22 mentions for Biogen and 7 mentions for Kymera Therapeutics. Biogen's average media sentiment score of 1.04 beat Kymera Therapeutics' score of 0.73 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
9 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

87.9% of Biogen shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Biogen beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

Kymera Therapeutics has a net margin of -285.33% compared to Roivant Sciences' net margin of -3,534.96%. Kymera Therapeutics' return on equity of -21.22% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-3,534.96% -22.94% -21.53%
Kymera Therapeutics -285.33%-21.22%-19.21%

64.8% of Roivant Sciences shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Roivant Sciences had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Roivant Sciences and 7 mentions for Kymera Therapeutics. Roivant Sciences' average media sentiment score of 0.77 beat Kymera Therapeutics' score of 0.73 indicating that Roivant Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
7 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Roivant Sciences has higher earnings, but lower revenue than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$8.26M3,496.17-$299.77M-$0.53N/A
Kymera Therapeutics$105M93.83-$311.35M-$3.24N/A

Roivant Sciences presently has a consensus price target of $45.64, suggesting a potential upside of 14.15%. Kymera Therapeutics has a consensus price target of $131.63, suggesting a potential upside of 11.09%. Given Roivant Sciences' higher probable upside, equities analysts plainly believe Roivant Sciences is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.88

Summary

Kymera Therapeutics beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Insmed?

Kymera Therapeutics (NASDAQ:KYMR) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Kymera Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Insmed has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Kymera Therapeutics has higher earnings, but lower revenue than Insmed. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$105M93.83-$311.35M-$3.24N/A
Insmed$606.42M44.65-$1.28B-$4.11N/A

Kymera Therapeutics presently has a consensus price target of $131.63, indicating a potential upside of 11.09%. Insmed has a consensus price target of $204.91, indicating a potential upside of 65.28%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.88
Insmed
1 Sell rating(s)
0 Hold rating(s)
22 Buy rating(s)
2 Strong Buy rating(s)
3.00

Insmed has a net margin of -76.94% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -21.22% -19.21%
Insmed -76.94%-123.94%-44.30%

In the previous week, Insmed had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Insmed and 7 mentions for Kymera Therapeutics. Insmed's average media sentiment score of 0.99 beat Kymera Therapeutics' score of 0.73 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Insmed beats Kymera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Kymera Therapeutics compare to Incyte?

Kymera Therapeutics (NASDAQ:KYMR) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Kymera Therapeutics presently has a consensus price target of $131.63, suggesting a potential upside of 11.09%. Incyte has a consensus price target of $124.05, suggesting a potential downside of 2.80%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.88
Incyte
0 Sell rating(s)
13 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.52

In the previous week, Incyte had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 10 mentions for Incyte and 7 mentions for Kymera Therapeutics. Incyte's average media sentiment score of 0.74 beat Kymera Therapeutics' score of 0.73 indicating that Incyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Incyte
4 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Incyte has a net margin of 27.71% compared to Kymera Therapeutics' net margin of -285.33%. Incyte's return on equity of 29.93% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -21.22% -19.21%
Incyte 27.71%29.93%22.88%

97.0% of Incyte shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kymera Therapeutics has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market. Comparatively, Incyte has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Incyte has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$105M93.83-$311.35M-$3.24N/A
Incyte$5.82B4.45$1.29B$7.8516.26

Summary

Incyte beats Kymera Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KYMR vs. The Competition

Export
MetricKymera TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.67B$3.84B$7.20B$13.72B
Dividend YieldN/A3.65%2.57%12.64%
P/E Ratio-36.5713.92273.3325.54
Price / Sales93.831,498.11674.5691.55
Price / CashN/A109.1477.0151.20
Price / Book6.1015.3810.466.31
Net Income-$311.35M-$22.78M$3.48B$357.99M
7 Day Performance3.06%-1.01%0.79%0.91%
1 Month Performance-2.39%-1.59%-0.30%-2.57%
1 Year Performance131.59%36.50%18.71%5.07%

Kymera Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KYMR
Kymera Therapeutics
1.6332 of 5 stars		$118.48
+1.8%		$131.63
+11.1%		+146.2%$9.67B$105MN/A273
ALNY
Alnylam Pharmaceuticals
4.1778 of 5 stars		$242.51
-3.0%		$376.67
+55.3%		-45.7%$32.41B$3.71B45.022,770
BIIB
Biogen
3.2361 of 5 stars		$215.88
-0.7%		$230.14
+6.6%		+51.2%$31.90B$9.89B38.217,500
ROIV
Roivant Sciences
2.376 of 5 stars		$39.57
-3.5%		$40.63
+2.7%		+161.6%$28.61B$7.53MN/A721
INSM
Insmed
3.2579 of 5 stars		$119.69
-4.5%		$205.52
+71.7%		-14.4%$26.16B$1.14BN/A1,664

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KYMR) was last updated on 9/18/2026 by MarketBeat.com Staff.
From Our Partners
Iran War: Why Is Trump Protecting THEM?
A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
$747 million in one quarter - with a 60% cash-flow target
The company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...
Monument Traders Alliance | Sponsoredtc pixel
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
“This is the Perfect Tech Stock”
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel